Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100718 | 0.99 | FYN (0.42) | FYNNOS3NOS1NOS2HRH3 | |
| SCHEMBL10100423 | 0.94 | FYN (0.41) | FYNNOS3NOS1NOS2HRH3 | |
| SCHEMBL10100446 | 0.94 | FYN (0.42) | FYNNOS3NOS1NOS2HRH3 | |
| SCHEMBL10100753 | 0.93 | FYN (0.41) | FYNHTR2CSIGMAR1NEK2HTR2B | |
| SCHEMBL10100773 | 0.88 | FYN (0.45) | FYNNOS3NOS1NOS2KCNN4 | |
| SCHEMBL10100566 | 0.87 | FYN (0.40) | FYNHTR2CSIGMAR1NEK2HTR2B | |
| SCHEMBL10100719 | 0.85 | NOS3 (0.35) | NOS3NOS1NOS2BACE1MCHR1 | |
| SCHEMBL10100708 | 0.85 | KCNN4 (0.41) | HRH3MCHR1HTR2AHTR2CKCNN4 | |
| SCHEMBL10100709 | 0.84 | SMN1; SMN2 (0.38) | HTR2AHTR2CAXLKCNN4SMN1; SMN2 | |
| SCHEMBL10100711 | 0.84 | BMPR1B (0.37) | FYNHRH3MCHR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | FYN 532/4885NOS3 2062/4885NOS1 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.